Table of Contents
- 1 What is better than Tremfya?
- 2 Does Tremfya lower your immune system?
- 3 Is Tremfya similar to Stelara?
- 4 How long does Tremfya take to work?
- 5 Is Tremfya better than Humira?
- 6 Is Tremfya better than Stelara?
- 7 Is Tremfya ® (guselkumab) superior to Cosentyx ® (Secukinumab)?
- 8 How common are serious adverse reactions to Tremfya and Cosentyx?
What is better than Tremfya?
On October 3, 2019, Eli Lilly published results from its head-to-head clinical study showing that its IL-17A inhibitor Taltz (ixekizumab) has superiority versus Janssen’s Tremfya (guselkumab) in moderate-to-severe plaque psoriasis patients.
Does Tremfya lower your immune system?
Tremfya may cause an upper respiratory infection such as the common cold. This is because Tremfya can weaken your immune system and make it less able to fight off germs that cause infection. Upper respiratory infections were the most commonly reported side effect in studies of Tremfya.
What is the annual cost of Tremfya?
Table 4CDR Cost Comparison Table for the Treatment of Plaque Psoriasis
| Drug / Comparator | Strength | Price ($) |
|---|---|---|
| Guselkumab (Tremfya) | 100 mg/mL | $3,059.7400a |
| Other Biologics | ||
| Adalimumab (Humira) | 40 mg/0.8 mL | $769.9700 |
| Etanercept (Enbrel) | 50 mg/mL 25 mg/vial | $405.9850 $202.9300 |
Does Tremfya reduce inflammation?
By blocking the effects of IL-23, Tremfya helps control the release of IL-17 and TNF-α, which reduces inflammation. It also decreases how many inflammatory cells are present within psoriatic lesions and helps prevent plaque formation and resolves tissue damage.
Is Tremfya similar to Stelara?
Like Stelara, Tremfya works by blocking interluekins, a class of proteins that regulate immune system responses. Other large pharmas, including Novartis, Eli Lilly, Sanofi and Regeneron, also have IL-inhibiting products on the market.
How long does Tremfya take to work?
Official Answer. It takes about 16 weeks for Tremfya to start working in most people, which is two doses of Tremfya because each dose is given 8 weeks apart.
Can Tremfya cause liver damage?
Elevated liver enzymes were reported more frequently in the TREMFYA group (2.6\%) than in the placebo group (1.9\%). Of the 21 subjects who were reported to have elevated liver enzymes in the TREMFYA group, all events except one were mild to moderate in severity and none of the events led to discontinuation of TREMFYA.
How effective is Tremfya?
Clinical studies looked at adults with moderate to severe plaque psoriasis who took either Tremfya or a placebo (treatment with no active drug). After 16 weeks of treatment, psoriasis symptoms eased or cleared up entirely in: 84\% to 85\% of people who took Tremfya. 7\% to 8\% of people who took the placebo.
Is Tremfya better than Humira?
TREMFYA®—Consistent PASI 90 Response Rates That Were Superior to Humira® at Weeks 16, 24, and 48. *P<0.001 vs Humira®. The same patients may not have responded at each time point.
Is Tremfya better than Stelara?
Patients receiving TREMFYA had a significantly greater number of visits from week 28 to week 40 with an Investigator’s Global Assessment (IGA) score of 0 or 1 and ≥2-grade improvement from week 16 vs patients receiving STELARA (P<0.001).
Does Tremfya cause liver damage?
What does Tremfya cure?
This medication is used to treat plaque psoriasis and psoriatic arthritis. Guselkumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural substance in your body (interleukin-23) that may cause inflammation and swelling.
Is Tremfya ® (guselkumab) superior to Cosentyx ® (Secukinumab)?
Horsham, Pennsylvania, December 12, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the ECLIPSE study demonstrating that TREMFYA ® (guselkumab) was superior to Cosentyx ® (secukinumab) * in treating adults with moderate to severe plaque psoriasis for the primary endpoint assessed at week 48.
How common are serious adverse reactions to Tremfya and Cosentyx?
Serious AEs were reported in 6.2 percent of patients receiving TREMFYA and 7.2 percent of patients receiving Cosentyx. Serious infections occurred in six patients receiving TREMFYA and five patients receiving Cosentyx. “Fortunately for patients, there are many good treatment options available for plaque psoriasis today.
How safe are Tremfya and Cosentyx in Eclipse?
The safety profiles observed for TREMFYA and Cosentyx in ECLIPSE were consistent with the known safety profiles seen in the respective registration trials and current prescribing information. Similar percentages of patients receiving TREMFYA (77.9 percent), and Cosentyx (81.6 percent) reported at least one adverse event (AE).
What is the efficacy of Tremfya for psoriasis?
Data from the multi-center, randomized, double-blind head-to-head Phase 3 study demonstrated that 84.5 percent of patients treated with TREMFYA achieved at least 90 percent improvement in their baseline Psoriasis Area Severity Index (PASI) score at week 48, compared with 70.0 percent of patients treated with Cosentyx (p<0.001).